journal article·2025-04-21Open access

Sorafenib—Drug Delivery Strategies in Primary Liver Cancer

Piotr Szyk, Beata Czarczynska-Goslinska, Marta Ziegler-Borowska, Igor Larrosa, Tomasz Goslinski

Abstract

Current primary liver cancer therapies, including sorafenib and transarterial chemoembolization, face significant limitations due to chemoresistance caused by impaired drug uptake, altered metabolism, and other genetic modulations. These challenges contribute to relapse rates of 50–80% within five years. The need for improved treatment strategies (adjuvant therapy, unsatisfactory enhanced permeability and retention (EPR) effect) has driven research into advanced drug delivery systems, including targeted nanoparticles, biomaterials, and combinatory approaches. Therefore, this review evaluates recent advancements in primary liver cancer pharmacotherapy, focusing on the potential of drug delivery systems for sorafenib and its derivatives. Approaches such as leveraging Kupffer cells for tumor migration or utilizing smaller NPs for inter-/intracellular delivery, address EPR limitations. Biomaterials and targeted therapies focusing on targeting have demonstrated effectiveness in increasing tumor-specific delivery, but clinical evidence remains limited. Combination therapies have emerged as an interesting solution to overcoming chemoresistance or to broadening therapeutic functionality. Biomimetic delivery systems, employing blood cells or exosomes, provide methods for targeting tumors, preventing metastasis, and strengthening immune responses. However, significant differences between preclinical models and human physiology remain a barrier to translating these findings into clinical success. Future research must focus on the development of adjuvant therapy and refining drug delivery systems to overcome the limitations of tumor heterogeneity and low drug accumulation.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Hepatocellular Carcinoma Treatment and Prognosis · Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Chair and Department of Chemical Technology of Drugs, Poznan University of Medical Sciences, Rokietnicka 3, 60-806 Poznan, Poland

Doctoral School, Poznan University of Medical Sciences, Bukowska 70, 60-812 Poznan, Poland

Chair and Department of Pharmaceutical Technology, Poznan University of Medical Sciences, Rokietnicka 3, 60-806 Poznan, Poland

Department of Biomedical Chemistry and Polymer Science, Faculty of Chemistry, Nicolaus Copernicus University in Torun, Gagarina 7, 87-100 Torun, Poland

Department of Chemistry, University of Manchester, Chemistry Building, Oxford Road, Manchester M13 9PL, UK

Funding

National Science Center

References (100+)

Show source-provided references
1. Epidemiology of Primary and Secondary Liver Cancers10.1055/s-2006-939841 ↗
2. Epidemiology of Primary Liver Cancer10.1055/s-2007-1007117 ↗
3. Update on the Diagnosis and Treatment of Hepatocellular Carcinoma
4. Capturing Circulating Tumor Cells of Hepatocellular Carcinoma10.1016/j.canlet.2012.07.024 ↗
5. Targeted Co-Delivery of PD-L1 Monoclonal Antibody and Sorafenib to Circulating Tumor Cells via Platelet-Functionalized Nanocarriers10.1016/j.bbrc.2023.05.124 ↗
6. Circulating Tumor Cells: Biology and Clinical Significance10.1038/s41392-021-00817-8 ↗
7. Neutrophils Promote Liver Metastasis via Mac-1–Mediated Interactions with Circulating Tumor Cells10.1158/0008-5472.CAN-11-2393 ↗
8. Espejo-Cruz, M.L., González-Rubio, S., Zamora-Olaya, J., Amado-Torres, V., Alejandre, R., Sánchez-Frías, M., Ciria, R., De La Mata, M., Rodríguez-Perálvarez, M., and Ferrín, G. (2021). Circulating Tumor Cells in Hepatocellular Carcinoma: A Comprehensive Review and Critical Appraisal. Int. J. Mol. Sci., 22.10.3390/ijms222313073 ↗
9. Quantified Postsurgical Small Cell Size CTCs and EpCAM+ Circulating Tumor Stem Cells with Cytogenetic Abnormalities in Hepatocellular Carcinoma Patients Determine Cancer Relapse10.1016/j.canlet.2017.10.004 ↗
10. BCLC Strategy for Prognosis Prediction and Treatment Recommendation: The 2022 Update10.1016/j.jhep.2021.11.018 ↗
11. Small-Molecule-Based Targeted Therapy in Liver Cancer10.1016/j.ymthe.2024.08.001 ↗
12. Fan, Q., Tian, H., Cheng, J., Zou, J., Luan, F., Qiao, J., Zhang, D., Tian, Y., Zhai, B., and Guo, D. (2024). Research Progress of Sorafenib Drug Delivery System in the Treatment of Hepatocellular Carcinoma: An Update. Biomed. Pharmacother., 177.10.1016/j.biopha.2024.117118 ↗
13. Zhang, Y., Zhang, W., Wang, Y., Zhu, J., Zhou, M., Peng, C., He, Z., Sun, J., Li, Z., and Gui, S. (2021). Emerging Nanotaxanes for Cancer Therapy. Biomaterials, 272.10.1016/j.biomaterials.2021.120790 ↗
14. Strategies and Challenges to Improve the Performance of Tumor-Associated Active Targeting10.1039/D0TB00289E ↗
15. Curcumin Analogues and Derivatives with Anti-Proliferative and Anti-Inflammatory Activity: Structural Characteristics and Molecular Targets10.1080/17460441.2019.1614560 ↗
16. Dziubańska-Kusibab, P.J., Nevedomskaya, E., and Haendler, B. (2024). Preclinical Anticipation of On- and Off-Target Resistance Mechanisms to Anti-Cancer Drugs: A Systematic Review. Int. J. Mol. Sci., 25.10.3390/ijms25020705 ↗
17. Therapeutic Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma Recurrence After Liver Transplantation: A Systematic Review and Meta-Analysis10.5152/tjg.2020.19877 ↗
18. Wang, L., Chen, M., Ran, X., Tang, H., and Cao, D. (2023). Sorafenib-Based Drug Delivery Systems: Applications and Perspectives. Polymers, 15.10.3390/polym15122638 ↗
19. Passive and Active Targeting in Cancer Therapy by Liposomes and Lipid Nanoparticles
20. Active Targeting of Drugs and Bioactive Molecules via Oral Administration by Ligand-Conjugated Lipidic Nanocarriers: Recent Advances10.1208/s12249-018-1262-2 ↗
21. Targeted Drug Delivery Systems for Curcumin in Breast Cancer Therapy10.2147/IJN.S410688 ↗
22. Traditional Chinese Medicine-Combination Therapies Utilizing Nanotechnology-Based Targeted Delivery Systems: A New Strategy for Antitumor Treatment10.2147/IJN.S197889 ↗
23. (2024, December 10). Liver Cancer Treatment—NCI, Available online: https://www.cancer.gov/types/liver/what-is-liver-cancer/treatment.
24. Tumor Ablation: Common Modalities and General Practices10.1053/j.tvir.2013.08.002 ↗
25. Bannangkoon, K., Hongsakul, K., and Tubtawee, T. (2024). Lipiodol Accumulation Patterns and Their Impact on Survival Outcomes in Transarterial Chemoembolization for Hepatocellular Carcinoma: A Single Institution Retrospective Analysis. Sci. Rep., 14.10.1038/s41598-024-69993-1 ↗
26. Lipiodol as an Imaging Biomarker of Tumor Response After Conventional Transarterial Chemoembolization: Prospective Clinical Validation in Patients with Primary and Secondary Liver Cancer10.1016/j.tranon.2020.01.003 ↗
27. Adjuvant I-131 Lipiodol After Resection or Radiofrequency Ablation for Hepatocellular Carcinoma10.1007/s00268-016-3502-5 ↗
28. Prediction of Complete Necrosis of Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Prior to Liver Transplantation10.5009/gnl.2009.3.4.285 ↗
29. Use of Lipiodol as a Drug-Delivery System for Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma: A Review10.1016/j.critrevonc.2013.07.003 ↗
30. Exploring the Enhanced Stability and Therapeutic Efficacy of Sorafenib-Cyclodextrin Inclusion Complex10.1016/j.molliq.2024.124701 ↗
31. Current State and Prospects of Nano-Delivery Systems for Sorafenib10.1080/00914037.2018.1429434 ↗
32. The Use of Lipid-Coated Nanodiamond to Improve Bioavailability and Efficacy of Sorafenib in Resisting Metastasis of Gastric Cancer10.1016/j.biomaterials.2014.02.024 ↗
33. Improving Oral Bioavailability of Sorafenib by Optimizing the “Spring” and “Parachute” Based on Molecular Interaction Mechanisms10.1021/acs.molpharmaceut.5b00837 ↗
34. Wiergowska, G., Stasiłowicz, A., Miklaszewski, A., Lewandowska, K., and Cielecka-Piontek, J. (2021). Structural Polymorphism of Sorafenib Tosylate as a Key Factor in Its Solubility Differentiation. Pharmaceutics, 13.10.3390/pharmaceutics13030384 ↗
35. Current Status of Sorafenib Nanoparticle Delivery Systems in the Treatment of Hepatocellular Carcinoma10.7150/thno.54822 ↗
36. Modeling and Optimization of Nanoemulsion Containing Sorafenib for Cancer Treatment by Response Surface Methodology10.1186/s13065-017-0248-6 ↗
37. Management of Hepatocellular Carcinoma: An Update Δσ10.1002/hep.24199 ↗
38. Sorafenib Exhibits Lower Toxicity and Comparable Efficacy to Sunitinib as a First-Line Treatment for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis10.1097/MD.0000000000034983 ↗
39. Renal Cell Carcinoma10.1038/nrdp.2017.9 ↗
40. Effects of Systemic Chemotherapy on the Liver10.1016/S1665-2681(19)31651-5 ↗
41. The Discovery and Development of Sorafenib for the Treatment of Thyroid Cancer10.1517/17460441.2015.1006194 ↗
42. Jiang, H., Wang, C., Zhang, A., Li, Y., Li, J., Li, Z., Yang, X., and Hou, Y. (2022). ATF4 Protects against Sorafenib-Induced Cardiotoxicity by Suppressing Ferroptosis. Biomed. Pharmacother., 153.10.1016/j.biopha.2022.113280 ↗
43. Targeted Therapy for Hepatocellular Carcinoma10.1038/s41392-020-00264-x ↗
44. Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors10.1200/JCO.2005.06.124 ↗
45. Sorafenib Improves Lipiodol Deposition in Transarterial Chemoembolization of Chinese Patients with Hepatocellular Carcinoma: A Long-Term, Retrospective Study10.18632/oncotarget.18811 ↗
46. Diagnosis and Management of Hepatocellular Carcinoma: Results of a Consensus Meeting of The Ottawa Hospital Cancer Centre10.3747/co.v17i2.555 ↗
47. Drug-Eluting Embolic Microspheres: State-of-the-Art and Emerging Clinical Applications10.1080/17425247.2021.1835858 ↗
49. Recent Advances of RAF (Rapidly Accelerated Fibrosarcoma) Inhibitors as Anti-Cancer Agents10.1016/j.ejmech.2018.09.005 ↗
50. RAS Proteins and Their Regulators in Human Disease10.1016/j.cell.2017.06.009 ↗
51. Targeting the RAS/RAF/MAPK Pathway for Cancer Therapy: From Mechanism to Clinical Studies10.1038/s41392-023-01705-z ↗
52. Masłowska, K., Halik, P.K., Tymecka, D., Misicka, A., and Gniazdowska, E. (2021). The Role of VEGF Receptors as Molecular Target in Nuclear Medicine for Cancer Diagnosis and Combination Therapy. Cancers, 13.10.3390/cancers13051072 ↗
53. Pottier, C., Fresnais, M., Gilon, M., Jérusalem, G., Longuespée, R., and Sounni, N.E. (2020). Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy. Cancers, 12.10.3390/cancers12030731 ↗
54. Preclinical Overview of Sorafenib, a Multikinase Inhibitor That Targets Both Raf and VEGF and PDGF Receptor Tyrosine Kinase Signaling10.1158/1535-7163.MCT-08-0013 ↗
55. Hendrixson, M., Gladkiy, Y., Thyagarajan, A., and Sahu, R.P. (2024). Efficacy of Sorafenib-Based Therapies for Non-Small Cell Lung Cancer. Med. Sci., 12.10.3390/medsci12020020 ↗
56. Leifheit, M.E., Johnson, G., Kuzel, T.M., Schneider, J.R., Barker, E., Yun, H.D., Ustun, C., Goldufsky, J.W., Gupta, K., and Marzo, A.L. (2024). Enhancing Therapeutic Efficacy of FLT3 Inhibitors with Combination Therapy for Treatment of Acute Myeloid Leukemia. Int. J. Mol. Sci., 25.10.3390/ijms25179448 ↗
57. Current and Future Treatment of Hepatocellular Carcinoma: An Updated Comprehensive Review
58. PharmGKB Summary: Sorafenib Pathways10.1097/FPC.0000000000000279 ↗
59. Adverse Events of Sorafenib in Hepatocellular Carcinoma Treatment
60. Part II: Liver Function in Oncology: Towards Safer Chemotherapy Use10.1016/S1470-2045(08)70307-3 ↗
61. Understanding Sorafenib-Induced Cardiovascular Toxicity: Mechanisms and Treatment Implications10.2147/DDDT.S443107 ↗
62. He, X., Sun, H., Jiang, Q., Chai, Y., Li, X., Wang, Z., Zhu, B., You, S., Li, B., and Hao, J. (2021). Hsa-miR-4277 Decelerates the Metabolism or Clearance of Sorafenib in HCC Cells and Enhances the Sensitivity of HCC Cells to Sorafenib by Targeting cyp3a4. Front. Oncol., 11.10.3389/fonc.2021.735447 ↗
63. Bæk Møller, N., Budolfsen, C., Grimm, D., Krüger, M., Infanger, M., Wehland, M., and Magnusson, N.E. (2019). Drug-Induced Hypertension Caused by Multikinase Inhibitors (Sorafenib, Sunitinib, Lenvatinib and Axitinib) in Renal Cell Carcinoma Treatment. Int. J. Mol. Sci., 20.10.3390/ijms20194712 ↗
64. Lack of Effect of Ketoconazole-Mediated CYP3A Inhibition on Sorafenib Clinical Pharmacokinetics10.1007/s00280-005-0068-6 ↗
65. Incidence and Risk of Sorafenib-Induced Hypertension: A Systematic Review and Meta-Analysis10.1111/jch.12273 ↗
66. Hsiao, W.-D., Peng, C.-Y., Chuang, P.-H., Lai, H.-C., Cheng, K.-S., Chou, J.-W., Chen, Y.-Y., Yu, C.-J., Feng, C.-L., and Su, W.-P. (2016). Evaluation of Dose-Efficacy of Sorafenib and Effect of Transarterial Chemoembolization in Hepatocellular Carcinoma Patients: A Retrospective Study. BMC Gastroenterol., 16.10.1186/s12876-016-0464-x ↗
67. Use of Transarterial Chemoembolization (TACE) and Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: US Regional Analysis of the GIDEON Registry10.1159/000367757 ↗
68. TACE Treatment in Patients with Sorafenib-Treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON10.1148/radiol.2015150667 ↗
69. Interim Analysis of START: Study in Asia of the Combination of TACE (Transcatheter Arterial Chemoembolization) with Sorafenib in Patients with Hepatocellular Carcinoma Trial10.1002/ijc.27925 ↗
70. Concurrent Sorafenib Therapy Extends the Interval to Subsequent TACE for Patients with Unresectable Hepatocellular Carcinoma10.1002/jso.24215 ↗
71. Controlled Drug Delivery Vehicles for Cancer Treatment and Their Performance10.1038/s41392-017-0004-3 ↗
72. Nanoparticle-Based Drug Delivery Systems for Cancer Therapy
73. Mechanisms of Targeted Drug Delivery for Liver Cancer: Active, Passive, and Subcellular Strategies
74. Nanoparticles for Cancer Therapy: Current Progress and Challenges10.1186/s11671-021-03628-6 ↗
75. Passive Targeting of Nanoparticles to Cancer: A Comprehensive Review of the Literature10.3892/mco.2014.356 ↗
76. Nanoparticles and Targeted Drug Delivery in Cancer Therapy10.1016/j.imlet.2017.07.015 ↗
77. Li, X., Yu, Q., Zhao, R., Guo, X., Liu, C., Zhang, K., Zhang, W., Liu, J., Yu, J., and Wang, S. (2022). Designer Exosomes for Targeted Delivery of a Novel Therapeutic Cargo to Enhance Sorafenib-Mediated Ferroptosis in Hepatocellular Carcinoma. Front. Oncol., 12.10.3389/fonc.2022.898156 ↗
78. Kiwi-Derived Extracellular Vesicles for Oral Delivery of Sorafenib10.1016/j.ejps.2023.106604 ↗
79. N-Acetyl-Galactosamine Modified Metal-Organic Frameworks to Inhibit the Growth and Pulmonary Metastasis of Liver Cancer Stem Cells through Targeted Chemotherapy and Starvation Therapy10.1016/j.actbio.2022.08.027 ↗
80. Apolipoprotein E Peptide-Guided Disulfide-Cross-Linked Micelles for Targeted Delivery of Sorafenib to Hepatocellular Carcinoma10.1021/acs.biomac.9b01419 ↗
81. Multi-Functionalized Dendrimers for Targeted Co-Delivery of Sorafenib and Paclitaxel in Liver Cancers10.1016/j.jddst.2021.102493 ↗
82. Shu, M., Tang, J., Chen, L., Zeng, Q., Li, C., Xiao, S., Jiang, Z., and Liu, J. (2021). Tumor Microenvironment Triple-Responsive Nanoparticles Enable Enhanced Tumor Penetration and Synergetic Chemo-Photodynamic Therapy. Biomaterials, 268.10.1016/j.biomaterials.2020.120574 ↗
83. Lin, Z., Li, S., Wu, Q., Qu, H., Shi, X., Wang, K., Tang, C., and Yin, C. (2024). In Situ Customized Apolipoprotein B48-Enriched Protein Corona Enhances Oral Gene Delivery of Chitosan-Based Nanoparticles. Biomaterials, 311.10.1016/j.biomaterials.2024.122704 ↗
84. An Apolipoprotein-Enriched Biomolecular Corona Switches the Cellular Uptake Mechanism and Trafficking Pathway of Lipid Nanoparticles10.1039/C7NR06437C ↗
85. Apolipoprotein E Binding Drives Structural and Compositional Rearrangement of mRNA-Containing Lipid Nanoparticles10.1021/acsnano.0c10064 ↗
86. Contribution of Kupffer Cells to Liposome Accumulation in the Liver10.1016/j.colsurfb.2017.07.014 ↗
87. Diagnostic Imaging and Therapeutic Application of Nanoparticles Targeting the Liver10.1039/C4TB01611D ↗
88. Nanoparticle–Liver Interactions: Cellular Uptake and Hepatobiliary Elimination10.1016/j.jconrel.2016.01.020 ↗
89. Alliance with EPR Effect: Combined Strategies to Improve the EPR Effect in the Tumor Microenvironment10.7150/thno.37198 ↗
90. EPR-Effect: Utilizing Size-Dependent Nanoparticle Delivery to Solid Tumors10.4155/tde.13.8 ↗
91. Size-Dependent EPR Effect of Polymeric Nanoparticles on Tumor Targeting10.1002/adhm.201901223 ↗
92. EPR: Evidence and Fallacy10.1016/j.jconrel.2014.03.057 ↗
93. To Exploit the Tumor Microenvironment: Since the EPR Effect Fails in the Clinic, What Is the Future of Nanomedicine?10.1016/j.jconrel.2016.11.015 ↗
94. Analysis of Nanoparticle Delivery to Tumours10.1038/natrevmats.2016.14 ↗
95. Mechanisms of Drug Resistance in HCC
96. Marin, J.J.G., Macias, R.I.R., Monte, M.J., Romero, M.R., Asensio, M., Sanchez-Martin, A., Cives-Losada, C., Temprano, A.G., Espinosa-Escudero, R., and Reviejo, M. (2020). Molecular Bases of Drug Resistance in Hepatocellular Carcinoma. Cancers, 12.10.3390/cancers12061663 ↗
97. (2024, December 24). The Human Protein Atlas. Available online: https://www.proteinatlas.org/.
98. Bismuth-Based Mesoporous Nanoball Carrying Sorafenib for Computed Tomography Imaging and Synergetic Chemoradiotherapy of Hepatocellular Carcinoma10.1002/adhm.202000650 ↗
99. Improved Drug Targeting to Liver Tumor by Sorafenib-Loaded Folate-Decorated Bovine Serum Albumin Nanoparticles10.1080/10717544.2018.1561766 ↗
100. Aconitic Acid Derived Carbon Dots: Conjugated Interaction for the Detection of Folic Acid and Fluorescence Targeted Imaging of Folate Receptor Overexpressed Cancer Cells10.1016/j.snb.2018.01.227 ↗